icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
9 Sep, 2020 14:17

EU reserves 200 mn more coronavirus vaccines amid BioNTech & Pfizer talks

EU reserves 200 mn more coronavirus vaccines amid BioNTech & Pfizer talks

The European Commission says it has concluded initial talks with Germany’s BioNTech and US-based Pfizer to reserve 200 million doses of their anticipated vaccine against Covid-19, with an option to buy a further 100 million.

The BioNTech-Pfizer effort is the sixth potential vaccine for which the Commission has struck – or plans to strike – an advance purchase agreement, having already concluded exploratory talks with Sanofi-GSK, Johnson & Johnson, CureVac and Moderna.

All EU member states would have the possibility to buy the resulting vaccine and could also donate it to poorer nations, or redirect to other European countries.

Also on rt.com Twice as many UK adults suffered depression during coronavirus pandemic, govt data shows

The EU supply is expected to be produced by BioNTech’s sites in Germany and Pfizer’s manufacturing site in Belgium, with deliveries starting by the end of the year, according to the companies.

They will seek regulatory review of their joint potential vaccine in October and, if approved, plan to supply up to 100 million doses worldwide by the end of 2020. This figure could reach about 1.3 billion doses by the end of 2021. The proposed agreement with the Commission would be the largest initial order for Pfizer and BioNTech to date.

Last month, the Commission reached a first agreement with AstraZeneca for at least 300 million doses of its potential vaccine. On Wednesday, the drugmaker announced it was suspending global trials of its experimental coronavirus vaccine over an unexplained illness in a participant.

Reacting to AstraZeneca’s move, the World Health Organization (WHO) said that safety is paramount in vaccine clinical trials and temporary suspensions are not unusual, Reuters reported. “We are pleased to see vaccine developers assuring the scientific integrity of the trials and abiding by the standard guidelines and rules for the development of vaccines,” the UN health agency said.

Also on rt.com Safety comes first, says Fauci, after ‘unfortunate’ pausing of AstraZeneca vaccine due to UK participant’s adverse reaction

If you like this story, share it with a friend!